RG
SAGE

Redmile Group’s Sage Therapeutics SAGE Stock Holding History

Redmile Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,450
Closed -$231K – 92
2019
Q1 		$231K Sell
1,450
-1,500
-51% -$217K 0.01% 76
2018
Q4 		$283K Buy
2,950
+780
+36% +$89.3K 0.01% 70
2018
Q3 		$307K Hold
2,170
– – 0.01% 76
2018
Q2 		$340K Buy
+2,170
New +$341K 0.01% 73
2016
Q2 		– Sell
-1,053,018
Closed -$33.8M – 58
2016
Q1 		$33.8M Buy
1,053,018
+94,644
+10% +$3.33M 3.46% 10
2015
Q4 		$55.9M Sell
958,374
-184,490
-16% -$9.14M 4.18% 9
2015
Q3 		$48.4M Buy
1,142,864
+852,514
+294% +$52.5M 3.66% 11
2015
Q2 		$21.2M Buy
+290,350
New +$18.7M 1.74% 22

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Redmile Group's SAGE Position: Q2 2019 in Review

Redmile Group sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 1,450 shares — an estimated $231K sold.

Redmile Group first reported a position in SAGE in Q2 2015 and held it in 8 quarters. The position peaked at $55.9M in Q4 2015. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Redmile Group reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Redmile Group sold 1,450 Sage Therapeutics shares in Q2 2019, an estimated $231K.
  • Redmile Group first reported a position in Sage Therapeutics in Q2 2015 and held it in 8 quarters.
  • Redmile Group's Sage Therapeutics position peaked at $55.9M in Q4 2015.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.